Written by Klarity Editorial Team
Published: Mar 4, 2026

If you’re a psychiatrist or PMHNP looking to grow your practice, ADHD might be the biggest opportunity staring you in the face right now.
Here’s why: Over 15 million U.S. adults have been diagnosed with ADHD — and that number has roughly doubled in the last few years. Wait times for evaluations have stretched to 3-6 months in many areas. Parents are desperate. Adults who’ve struggled their whole lives are finally seeking help. And honestly? There aren’t nearly enough providers to meet the demand.
This isn’t about chasing trends. It’s about meeting a massive, underserved need — and building a financially sustainable practice while you do it.
Let me walk you through what’s actually working for ADHD patient acquisition in 2026, what the economics really look like, and how to navigate the regulatory landscape without getting burned.
The demand spike is real. Clinics across the country report that adult ADHD evaluation requests have doubled or tripled since 2020. Social media awareness, the pandemic’s work-from-home shift revealing concentration issues, and reduced mental health stigma all converged at once.
The numbers back this up: ADHD is now the second-most common psychiatric disorder in adults (after anxiety), affecting about 4-5% of the adult population. Yet historically, up to 80% of adults with ADHD were never diagnosed or treated.
That’s changing fast. And it’s creating a business opportunity.
Here’s what this means for your practice:
High patient lifetime value: ADHD isn’t a 6-session therapy case. These patients need ongoing medication management — monthly or quarterly appointments for years. One ADHD patient can represent $3,000-10,000+ in revenue over their treatment course.
Strong referral potential: Satisfied ADHD patients refer like crazy. They’re often relieved to finally get help and eager to share that with friends, family members, or online communities.
Less competition than you’d think: Yes, everyone’s talking about ADHD. But most psychiatrists are already full, and many aren’t taking new patients. If you can offer reasonable availability (especially via telehealth), you’ll stand out immediately.
The catch? You need to actually find these patients efficiently. That’s where most providers struggle.
Here’s where I need to be straight with you: acquiring psychiatric patients isn’t cheap or easy if you’re doing it yourself.
The myth: ‘Just run some Google Ads at $30-50 per patient and you’re golden!’
The reality: True patient acquisition costs are typically $200-500+ when you factor in everything — agency fees, ad spend optimization, staff time qualifying leads, no-shows from cold traffic, and the months of SEO investment before you see results.
Let me break down what each channel actually costs:
SEO (Search Engine Optimization)
Google Ads (PPC)
Directory Listings (Psychology Today, Zocdoc, etc.)
The bottom line: If you’re spending $3,000-5,000/month on marketing with uncertain results, you’re gambling. Some months you might get 10 new patients. Other months, two.
This is where platforms like Klarity Health change the equation entirely.
Instead of paying upfront for marketing that might work, you pay only when a qualified patient actually books with you. It’s a pay-per-appointment model — similar to Zocdoc, but with better patient quality and built-in telehealth infrastructure.
Here’s why this model makes financial sense:
✓ No upfront marketing spend — Zero dollars at risk before you see a patient
✓ Pre-qualified patients — Already matched to your specialty and availability, significantly higher show rates than cold leads
✓ No wasted ad spend — You’re not paying $40/click for tire-kickers who never book
✓ Built-in telehealth platform — No separate EMR or video costs to worry about
✓ Both insurance and cash-pay flow — Diversified revenue streams
✓ You control your schedule — Only pay the standard listing fee when you actually see patients
The math is simple: Would you rather spend $4,000/month on marketing that might bring in 8-10 new patients… or pay a per-appointment fee only for the patients you actually see, with guaranteed ROI?
For most providers — especially those starting out, scaling up, or just tired of the marketing treadmill — the answer is obvious.
If you are going to invest in marketing yourself (or alongside a platform), here’s what’s worth your time:
Fill out everything. List ADHD specifically. Get patient reviews. This alone can generate 2-5 patients per month with minimal effort.
Most primary care docs are relieved to refer ADHD cases out — they don’t have time for 90-minute evaluations and medication titration.
Action steps:
One good referral partnership can send you 20+ patients per year. That’s essentially free marketing.
If you’re only seeing patients within 10 miles of your office, you’re leaving money on the table.
In states like Texas or Florida (with severe psychiatrist shortages), advertising ADHD telehealth services statewide can instantly 10x your addressable market.
In urban markets (NYC, SF, LA), telehealth lets you capture suburban and exurban patients who don’t want to commute.
Just make sure you understand your state’s telehealth rules (more on that below).
If you are investing in SEO or content marketing, focus on what ADHD patients are actually searching for:
Write blog posts or record videos answering these questions. Be helpful, not salesy. Google rewards expertise, and patients trust providers who’ve already helped them understand their condition.
ADHD treatment involves Schedule II controlled substances (stimulants), which means you need to stay on top of both federal and state rules. Here’s the current lay of the land:
The DEA has extended pandemic-era telehealth flexibilities through December 31, 2026. This means you can prescribe controlled ADHD medications (Adderall, Vyvanse, etc.) via telehealth to new patients without an initial in-person visit.
This is huge for telehealth-based ADHD practices.
But — and this is critical — state laws can override federal permissions.
New York reinstated an in-person requirement as of May 2025. You cannot start a stimulant prescription via telehealth alone in NY anymore. Workaround: hybrid models (initial in-person, then telehealth follow-ups).
Florida generally prohibits telehealth prescribing of Schedule II drugs except for psychiatric treatment — which ADHD qualifies as. So you’re good in Florida if you’re treating ADHD as a psychiatric condition (which you are). Just document it properly.
Texas allows telehealth prescribing for ADHD by physicians. But here’s the kicker for NPs: Texas nurse practitioners cannot prescribe Schedule II stimulants in outpatient settings. Only MDs/DOs can. If you’re a PMHNP in Texas, you’ll need a collaborating physician to write those scripts.
California, Illinois, Pennsylvania: These states generally align with federal rules. No special in-person requirements for telehealth stimulant prescribing (as of 2026). Always verify current rules with your state board.
Every state requires you to check the Prescription Drug Monitoring Program before prescribing controlled substances. For ADHD patients on stimulants, you’ll need to:
Skipping this step is how providers get into trouble. Don’t cut corners.
If you’re a psychiatric nurse practitioner, your ability to practice independently and prescribe ADHD medications varies dramatically by state:
Full Practice Authority (NPs can practice independently after supervised hours):
Restricted or Collaborative Practice:
Bottom line for PMHNPs: Know your state’s rules before you build your practice model. In some states, you need an MD partner to make ADHD med management work.
The opportunity: Texas has one of the worst psychiatrist-to-population ratios in the country (1:8,966). Huge underserved areas, especially outside Houston/Dallas/Austin.
The catch: NPs can’t prescribe stimulants. Telehealth is allowed for MDs/DOs, but you’ll need to navigate collaboration requirements if you’re scaling with NPs.
Strategy: MD-led telehealth practice targeting underserved regions. Build referral relationships with rural primary care clinics.
The opportunity: Similar provider shortage (1:8,577 ratio). Growing population, including many families relocating to FL.
The rules: Telehealth prescribing of stimulants is allowed for psychiatric treatment. Just document that you’re treating ADHD as a psychiatric condition. NPs need physician collaboration.
Strategy: Position yourself as the ‘fast-access ADHD specialist’ via telehealth. Many patients wait months for appointments in South Florida.
The reality: In-person exam required before prescribing stimulants (as of May 2025). This makes purely virtual ADHD practices difficult in NY.
The opportunity: NYC metro has massive demand despite high provider density. Lots of adult professionals seeking ADHD diagnosis.
Strategy: Offer hybrid care — initial in-person evaluation in your office or partner clinic, then telehealth follow-ups for med management. Market the convenience angle (only one trip required).
The opportunity: 40 million people. ADHD awareness high, especially in tech hubs (SF, LA).
The advantage: NPs can practice independently as of 2026, opening opportunities for PMHNP-led practices.
Strategy: Differentiate through specialization (adult ADHD, ADHD + anxiety comorbidity, etc.) or serve rural/inland areas via telehealth where competition is lower.
The opportunity: Strong NP practice authority. Downstate Illinois (outside Chicago) has significant provider shortages.
Strategy: Chicago-based providers can offer telehealth to entire state. PMHNPs can operate independently after meeting hour requirements, making this ideal for NP-owned practices.
The situation: Collaboration required for NPs (for now). Bills pending to grant independence after 3,600 hours.
The opportunity: Philadelphia and Pittsburgh well-served, but central/northern PA underserved.
Strategy: Multi-state providers can leverage PA’s IMLC membership (Interstate Medical Licensure Compact) for faster licensing. Target suburban and rural markets via telehealth.
As ADHD treatment has boomed, so has regulatory scrutiny. Here’s how to stay on the right side of the line:
1. ‘Pill Mill’ Perception
Some telehealth startups have been investigated for rubber-stamping stimulant prescriptions. Don’t be that practice.
How to protect yourself:
2. State Law Violations
The federal extension allowing telehealth prescribing doesn’t override state laws. If your state requires in-person (like NY), you must comply or risk your license.
3. PDMP Non-Compliance
This is low-hanging fruit for regulators. Check it. Document it. Every time.
4. Practicing Without Proper Licensure
You must be licensed in the state where your patient is located during the telehealth visit. Not where you’re sitting. Not where your business is incorporated. Where the patient is.
If you’re seeing patients in multiple states, you need multiple licenses. There’s no shortcut.
Q: How long does it realistically take to build a full ADHD caseload?
If you’re starting from scratch with your own marketing: 6-12 months to get to 20-30 patients, assuming consistent effort.
With a platform handling patient acquisition (like Klarity): You can start seeing patients within weeks of onboarding, and reach capacity in 2-4 months depending on your availability.
Referral networks take longer (6+ months to build) but provide steady, high-quality patients once established.
Q: What’s a realistic income target for an ADHD-focused practice?
A full-time psychiatrist seeing 15-20 ADHD patients per week (mix of evals and follow-ups) can generate $250,000-400,000+ annually, depending on insurance vs. cash-pay mix and efficiency.
PMHNPs typically earn $150,000-250,000 full-time in an ADHD-focused practice, with higher earnings possible in independent cash-pay models.
Q: Should I take insurance or go cash-pay?
Insurance pros: Larger patient pool, more stable income, easier to fill your schedule
Cash-pay pros: Higher per-appointment revenue, less administrative hassle, more control
Reality: Most successful practices use a hybrid model — credentialed with 2-3 major insurers for volume, plus some cash-pay slots for premium pricing. Platforms like Klarity offer both.
Q: How do I handle the Adderall shortage and patient anxiety about medication availability?
Be proactive:
Turn this into a trust-building opportunity by showing you’re on top of the issue and have backup plans.
Q: Can I prescribe stimulants to out-of-state patients if I’m licensed there?
It depends on both states’ laws. Generally:
Q: What if I want to offer both therapy and medication management for ADHD?
This is actually a strong value proposition — comprehensive ADHD care under one roof. Many patients struggle to coordinate between a therapist and prescriber.
If you’re not doing therapy yourself, partner with a licensed therapist or psychologist. Build a referral network so you can offer ‘we’ll handle both’ as a selling point.
Q: How do I compete with online ADHD companies like Done, Cerebral, or Ahead?
Focus on what they can’t offer:
Many patients have had bad experiences with app-based services and are seeking ‘real’ providers. That’s your opening.
Here’s what I want you to take away from this:
1. The ADHD patient demand is massive and real. This isn’t hype. Wait lists are 3-6 months in many areas. Adults who’ve struggled for decades are finally seeking help. You can build a thriving practice around this need.
2. DIY marketing is expensive and slow. If you’re spending $3,000-5,000/month on SEO and Google Ads with uncertain results, you’re gambling with your cash flow. It can work, but it takes expertise, time, and patience most providers don’t have.
3. Pay-per-appointment platforms eliminate the risk. Instead of paying upfront for marketing that might not work, you pay only when qualified patients book with you. That’s guaranteed ROI vs. gambling.
4. Telehealth is your growth lever — if you understand the regulatory landscape. Know your state’s rules. Get licensed in multiple states if you want to scale. Stay compliant with PDMP checks and prescribing requirements.
5. The providers who win are the ones who solve the patient acquisition problem efficiently. Whether that’s through a platform, a referral network, or a well-executed marketing strategy, you need a system that brings in qualified patients predictably.
The ADHD treatment gap isn’t going away anytime soon. The question is whether you’ll capture that demand — or watch someone else do it.
Ready to see how Klarity Health can help you grow your ADHD patient base without the marketing headaches? Learn more about joining our provider network or schedule a call to discuss your practice goals.
| Source & URL | Type of Source | Published / Updated | Reliability |
|---|---|---|---|
| HHS Press Release – DEA Telemedicine Flexibility Extension (hhs.gov) | Official Government (HHS) | Jan 2, 2026 | High – Government publication describing current federal telehealth policy (authoritative for federal rule status). |
| AP News – More adults sought help for ADHD during pandemic (apnews.com) | News Media (Associated Press) | Jan 10, 2024 | High – AP is a highly reliable newswire. This article references a JAMA Psychiatry study and expert quotes on ADHD Rx trends. |
| AP News – Rise in diagnoses prompts adults to ask: Do I have ADHD? (apnews.com) | News Media (Associated Press) | Jan 27, 2025 | High – AP piece citing CDC study data (statistics on adult ADHD diagnoses) and expert input from Ohio State University. |
| The Guardian – US adult ADHD system falling behind (theguardian.com) | News Media (International) | July 8, 2023 | Medium – Guardian is reputable; this feature has interviews with clinicians and cites trends (demand ‘doubled or tripled’, ‘80% undiagnosed’ etc.). |
| Medscape – First US Adult ADHD Guidelines on the way? (medscape.com) | Medical News/Trade | Apr 11, 2024 | High – Medscape (with expert quotes) noting prevalence (10–11 million adults, 4.4%) and psychiatry attitudes. |
All sources verified as of February 9, 2026. Full citations available upon request.
Find the right provider for your needs — select your state to find expert care near you.